Page 293 - ATP-P 11th Ed

Description: Oral antibacterial combination consisting of the semisynthetic antibiotic amoxicil-
lin and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid).
Indications:
• Lower respiratory tract infections
• Otitis media
• Sinusitis
• Skin and skin structure infections
• Urinary tract infections
Adult dose: The usual adult dose is one 875mg tablet q12hr.
Pediatric dose:
• 30mg/kg/day in divided doses (q8–12hr) produces less nausea and diarrhea and is
effective for most infections.
• Pediatric patients weighing 40kg or more should be dosed according to the adult
recommendations.
K9 Dose:
• Skin infections 13.75–22mg/kg PO bid for 10–14 days. UTIs 12.5mg/kg PO bid for 7–10
days SECTION 3
Contraindications:
• SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHY-
LACTIC) REACTIONS CAN OCCUR IN INDIVIDUALS WITH A HISTORY OF
PENICILLIN HYPERSENSITIVITY
• Do not use in patients with a history of liver failure.
Pregnancy Category B
Side-effects: The majority of side-effects observed in clinical trials were of a mild and
transient nature but can include:
• Diarrhea/loose stools
• Nausea
• Skin rashes and urticaria
• Vomiting
• Vaginitis
Adverse reactions:
• Hypersensitivity reactions
• Hepatic dysfunction
• Blood and lymphatic dysfunction (likely hypersensitivity-related)
TMEP use:
• Cellulitis/Cutaneous Abscess Protocol
• Dental Pain Protocol
• Flank Pain Protocol
• Head and Neck Infection Protocol
• Ingrown Toenail Protocol
ATP-P Handbook 11th Edition 283